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Alterations in nucleoli, including increased numbers,
increased size, altered architecture and increased function
are hallmarks of prostate cancer cells. The mechanisms
that result in increased nucleolar size, number and
function in prostate cancer have not been fully elucidated.
The nucleolus is formed around repeats of a transcrip-
tional unit encoding a 45S ribosomal RNA (rRNA)
precursor that is then processed to yield the mature 18S,
5.8S and 28S RNA species. Although it has been generally
accepted that tumor cells overexpress rRNA species, this
has not been examined in clinical prostate cancer. We ﬁnd
that indeed levels of the 45S rRNA, 28S, 18S and 5.8S are
overexpressed in the majority of human primary prostate
cancer specimens as compared with matched benign
tissues. One mechanism that can alter nucleolar function
and structure in cancer cells is hypomethylation of CpG
dinucleotides of the upstream rDNA promoter region.
However, this mechanism has not been examined in
prostate cancer. To determine whether rRNA overexpres-
sion could be explained by hypomethylation of these
CpG sites, we also evaluated the DNA methylation status
of the rDNA promoter in prostate cancer cell lines and the
clinical specimens. Bisulﬁte sequencing of genomic DNA
revealed two roughly equal populations of loci in cell lines
consisting of those that contained densely methylated
deoxycytidine residues within CpGs and those that
were largely unmethylated. All clinical specimens also
contained two populations with no marked changes in
methylation of this region in cancer as compared with
normal. We recently reported that MYC can regulate
rRNA levels in human prostate cancer; here we show that
MYC mRNA levels are correlated with 45S, 18S and 5.8S
rRNA levels. Further, as a surrogate for nucleolar size
and number, we examined the expression of ﬁbrillarin,
which did not correlate with rRNA levels. We conclude
that rRNA levels are increased in human prostate cancer,
but that hypomethylation of the rDNA promoter does not
explain this increase, nor does hypomethylation explain
alterations in nucleolar number and structure in prostate
cancer cells. Rather, rRNA levels and nucleolar size and
number relate more closely to MYC overexpression.
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Introduction
Changes in nuclear morphology such as enlargement
and increased numbers of nucleoli are diagnostic hall-
marks of many types of cancer cells, including prostate
cancer and its putative precursor lesion, high-grade
prostatic intraepithelial neoplasia (Bostwick et al., 1996;
Epstein and Yang, 2002; Fischer et al., 2004). The
nucleolus is the site of ribosome biogenesis where
ribosomal RNA (rRNA) is transcribed, processed,
modiﬁed and assembled into ribosomal subunits.
Regulation of ribosome biogenesis is tightly linked to
the control of cellular growth and proliferation. rRNA
transcription and ribosome biogenesis are controlled by
a number of cellular pathways such as the PI3 kinase/
mTOR, MYC and RAS/ERK pathways (Derenzini
et al., 1998; Ruggero and Pandolﬁ, 2003; Fischer
et al., 2004; McStay and Grummt, 2008; Drygin et al.,
2010; Grummt, 2010; Grummt and Voit, 2010), and
increased rRNA synthesis and ribosome biogenesis
are thought to be important molecular alterations
that occur very commonly in cancer cells (Ruggero
and Pandolﬁ, 2003; White, 2005; Williamson et al.,
2006; Drygin et al., 2010). Therefore, elucidating the
mechanisms by which nucleolar enlargement, number
and function are deregulated in cancer initiation and
progression is likely to be critical to our understanding
of abnormal cell proliferation control in prostate cancer.
The nucleolus is formed around tandem repeats of the
ribosomal RNA genes (rDNA), each of which contains
a promoter region (Figure 1). Human rDNA repeat
units comprise B43kb (Gonzalez and Sylvester, 1995).
Sequences encoding pre-rRNA (18S, 5.8S and 28S) are
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B30kb, which are largely non-transcribed. rDNA
repeats are generally found in two major chromatin
states. In all species examined, including humans, B1/2
of the repeat units are present in densely compact
‘heterochromatin’ that is not accessible to the cross-
linking agent psoralen in vivo (McStay and Grummt,
2008). The other 1/2 of the repeats is generally accessible
to psoralen and these contain a more open ‘euchromatic’
chromatin structure. The rDNA promoter consists of a
core promoter element adjacent to the transcription
start site and a nearby upstream control element
(Figures 1b and c) (Haltiner et al., 1986). In human
cells, deoxycytidine methylation of the B25 CpGs
residing within the promoter is present in two major
patterns. For each repeat unit, either this entire region
contains largely unmethylated CpGs or the entire region
contains largely methylated CpGs. In general, B1/2 of
the repeats show each type of conﬁguration (McStay
and Grummt, 2008), and the closed psoralen-inacces-
sible repeats correspond to those containing densely
methylated CpG dinucleotides in the promoter regions,
whereas the psoralen-accessible repeats are largely un-
methylated in the promoter regions (McStay and
Grummt, 2008). Further, the densely methylated psoralen
inaccessible repeats are transcriptionally inactive. And, of
the non-methylated repeats, it appears that only a limited
number of these units are active at any one time.
Increases in rRNA synthesis can occur by increases in
initiation, elongation or processing of previously
accessible ‘euchromatic’ repeats, or by recruitment
of previously inactivated heterochromatic repeats to
increase the number of active repeats, or by both of
these mechanisms (Grummt, 2010). A number of factors
activate the expression of rRNA levels by RNA
polymerase I in the non-heterochromatic repeats, the
most well studied of which is upstream-binding factor.
Upstream-binding factor is a high mobility group
box DNA-binding protein, which binds to the rDNA
promoter and recruits selectivity factor 1 (SL1), a
GTGTGTCCC GGTCGTAGGA GGGGCCGGCC
GAAAATGCTT CCGGCTCCCG CTCTGGAGAC ACGGGCCGGC CCCTGCGTGT
GGCCAGGGCG GCCGGGAGGG CGTCCCCGGC CCGGCGCTGC TCCCGCGTGT
CCTACGACCG GGACACACGT CCTGGGGTTG ACCAGAGGGC CCCGGGCGCT
CCGTGTGTGG CTGCGATGGT GGCGTTTTTG GGGACAGGTG TCCGTGTCGC
GCGTCGCCTG GGCCGGCGGC GTGGTCGGTG ACGCGACCTC CCGGCCCCGG
GGGAGGTATA TCTTTCGCTC CGAGTCGGCA TTTTGGGCCG CCGGGTTATT
GCTGACACGC TGTCCTCTGG CGACCTGTCG CTGGAGAGGT TGGGCCTCCG
GATGCGCGCG GGGCTCTGGC CTCACGGTGA C
+1 +8 +21 +29
-9 -12 -25 -30 -35
-53 -59 -67 -69 -75 -84 -81 -87 -96 -99
-103 -101 -108 -128
-154
-137 -149
-158
v
v
v v
1 4 8 13 18 27 32 42 42.9
Transcribed (47S) Non-Transcribed Promoter
18S 28S 5.8S
Upstream Control Element
(-186 ~ -50)
Core Promoter
(-50 ~ +20) 
DNA base number
(kb)
Intrergenic spacer (IGS)
Figure 1 The human rDNA promoter region. (a) Genotyping of rDNA promoter region. The sequence of the rDNA promoter as
shown was identical for all prostate cancer tissues and normal tissues, as well as all the cell lines. In this map, primer sequences for
genotyping are indicated by the underlined regions and the primer sequences for bisulﬁte sequencing are indicated as dotted underlines.
CpG dinucleotides are boxed with the location marked relative to the transcription start site (arrow). Discrepancies with the published
DNA sequence (U13369) are marked. Nucleotides that show base substitutions as compared with the reference U13369 seqeunce are
illustrated with dots above the DNA sequence. Deletions (generally a single base), relative to the reference sequence, are marked by a
‘v ‘between nucleotides. (b) Schematic representation of a single human rDNA repeat. The approximate positions relative to the
transcription start site are indicated (DNA base number in kb). (c) Vertical lines indicate locations of CpG dinucleotides on the 45S
rRNA promoter relative to the transcription start site, indicated with the dashed curved arrow, with primer pairs used for bisulﬁte
mapping marked by inward pointing arrows.
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OncogeneTBP–TAFI complex that regulates transcription initia-
tion by RNA polymerase I (Pol I). Upstream-binding
factor activity is tightly regulated by association with
transcription factors and post-translational modiﬁca-
tions such as acetylation and phosphorylation.
In terms of silent heterochromatic regions a number
of studies indicate that the nucleolar remodeling
complex is required to maintain DNA methylation
of the silent repeats by recruiting DNA methyltrans-
ferases (Grummt, 2010). In liver cancer, a recent report
indicated that the tumor cells showed decreased
methylation of the promoter region and that this
correlated with increased rRNA transcription (Ghoshal
et al., 2004). In prostate cancer, although there are
common nucleolar structural abnormalities and in-
creased expression of a number of genes whose products
localize to nucleoli (Fischer et al., 2004), (Koh et al.,
2010), it has not been determined previously whether
rRNA levels are actually increased, nor has it been
determined whether cancer-cell-speciﬁc epigenetic al-
terations of the rDNA promoter occur. That altered
methylation of the rDNA loci can affect nucleolar
structure and function was shown recently as targeted
disruption of DNMT1 and/or DMT3b resulted in
disrupted nucleolar architecture and complex alterations
in rRNA transcription and processing (Espada et al.,
2007; Gagnon-Kugler et al., 2009). Therefore, we
undertook the current study to examine the hypotheses
that rRNA levels are increased in human prostate cancer
cells, and that these levels as well as nucleolar structural
abnormalities (for example, increased size and number)
are related to hypomethylation of the rDNA promoter
region.
Results
To determine whether rRNA levels were elevated in
human prostate cancer, we isolated total RNA from a
series of tumor and normal (non-neoplastic regions)
pairs from fresh frozen tissue samples obtained from
radical prostatectomy specimens (Table 1) and per-
formed real time quantitative reverse transcriptase PCR
for the 45S precursor form as well as the 28S, 18S and
5.8S mature rRNA forms (Figure 2). The 45S precursor
is very short lived, and is considered a sign of new
transcription. Although each of the forms of rRNA
measured was higher in tumor samples, as compared
with matched normal samples, these increases reached
statistical signiﬁcance only for the 45S and 5.8S forms.
Similar overall results were obtained if we normalized
the rRNA species levels to total RNA, as well as to
DNA content (data not shown). These results suggest
that active transcription of the precursor rRNA
transcript, as well as the steady state levels of at least
some of the mature rRNA forms, are signiﬁcantly higher
in human prostate cancer samples as compared with
matched non-cancerous samples. Table 2 shows that
the levels of the various rRNA species correlated with
each other in tumor samples. There was no correlation
between rRNA levels and Gleason score or pathological
stage for any of the species measured (not shown).
There are a number of mechanisms by which
rRNA transcription and processing are regulated. One
Table 1 Clinical/pathological characteristics of patient samples
Age Margins Gleason
sum
Gleason
primary
Gleason
secondary
Gleason
tertiary
Pstage
39 Negative 7 4 3 T3AN0MX
52 Negative 6 3 3 T2N0MX
54 Positive 7 4 3 5 T3AN0MX
54 Negative 6 3 3 T2N0MX
55 Negative 7 3 4 T3BN0MX
56 Negative 9 4 5 3 T2N0MX
56 Negative 7 3 4 T3AN0MX
57 Positive 6 3 3 T3AN0MX
57 Positive 7 3 4 T3AN0MX
58 Negative 7 4 3 5 T3BN0MX
58 Positive 7 3 4 T3AN0MX
58 Negative 7 4 3 T3BN0MX
59 Negative 7 3 4 T3BN0MX
60 Negative 7 3 4 T3AN0MX
61 Negative 7 4 3 5 T3AN0MX
61 Negative 7 3 4 T2N0MX
62 Negative 7 3 4 5 T3AN0MX
62 Positive 8 4 4 5 T3AN0MX
63 Positive 7 3 4 T3AN0MX
65 Negative 7 3 4 T2N0MX
65 Negative 7 3 4 5 T3AN0MX
These are data from the radical prostatectomy specimens. PStage
indicates pathological stage (AJCC/UICC, seventh edition) at radical
prostatectomy. There were 18 Caucasian and 2 African-American
patients.
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Figure 2 rRNA levels are increased in human prostate cancer
tissues. Box plots show the relative levels of the indicated rRNA
species in tumor compared with non-tumor (normal) tissue.
The sign test was used to test the equality of the matched pairs
of observation (P-values are indicated).
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Oncogenemechanism posited suggests that the extent of CpG
methylation in the rRNA promoter correlates with
rRNA levels (Ghoshal et al., 2004). To determine
the methylation status of the rDNA promoter we ﬁrst
sought to determine the sequence of the human rDNA
promoter region in our cell lines and samples. PCR
primers were selected to amplify a 420bp region that
encompassed our bisulﬁte-sequencing primers and con-
tained additional ﬂanking sequences on either side. The
resulting PCR products for each subject were sequenced
using the M13 reverse primer. When the sequences of
these non-bisulﬁte-treated genotyping sequences were
compared with the published reference sequence for the
rRNA promoter region (Genebank accession number:
U13369) a number of discrepancies were identiﬁed.
Interestingly, these sequence variants that we identiﬁed
were the same as those previously uncovered in a study
using human brain DNA (McGowan et al., 2008).
Therefore, all the subsequent bisulﬁte sequencing results
of the DNA from cell lines and subjects in this study
were compared with this ‘corrected’ sequence (shown in
Figure 1a).
As a control to determine the ability of our bisulﬁte-
sequencing approach to detect methylation changes
in the rDNA promoter region, we ﬁrst compared the
methylation status in a series of isogenic colo-rectal
carcinoma cell lines that contain either wild-type or
disrupted versions of DNMT1, DMNT3b or both.
A previous study found that targeted disruption of both
DNMT1 and DNMT3b resulted in a total lack of
methylation in this region (Gagnon-Kugler et al., 2009).
Figure 3 shows results of bisulﬁte sequencing of the
rDNA promoter in the colon cancer cell line HCT116
wild-type (HCT116_WT) or knockout mutants that
lack either DNMT1 (HCT116_KO1), DNMT3b
(HCT116_KO3b) or both genes (HCT116_DKO). In
HCT116_WT, as expected there were two populations
of alleles, one densely methylated and the other
unmethylated. In HCT116_KO1 cells, there was a
reduction in methylation, whereas in HCT116_KO3b
cells there was less of a change overall, although
the fraction of unmethylated alleles was somewhat
increased. In HCT116_DKO cells there was a complete
loss of methylation.
To more deﬁnitively quantify the extent of methylation
of these regions, and to further validate the quantitative
nature of our bisulﬁte sequencing approach, we estab-
lished a real-time methylation-speciﬁc PCR assay for
the rDNA promoter. We designed primers, which are
complementary to methylated  158,  9a n dþ8C p G s .
It was conﬁrmed by sequencing that PCR products
obtained using these primer sets were limited to methy-
lated repeats (data not shown). Consistent with the
DNA methylation map of HCT116 cells and their
mutants, the normalized methylation indices (NIMs) were
0.41 for HCT116_WT, 0.06 for HCT116_KO1, 0.33 for
HCT116_KO3B and 0 for HCT116_DKO, respectively
(Figure 3). Taken together, these ﬁndings demonstrate
that our bisulﬁte genomic sequencing approach is
reﬂective of the overall methylation status of the rDNA
promoter region.
We next used our bisulﬁte DNA sequencing approach
to determine the methylation status of prostate cancer
cell lines and normal prostatic epithelial cells. All of the
prostate cancer cell lines and the prostate epithelial cells
showed two populations of alleles as seen in the
HCT116 wild-type cells (Figure 4). These results indicate
that the prostate cancer cell lines tested do not contain
hypomethylated alleles in this region, even though they
tend to have large, abnormal appearing nucleoli and
increased numbers of nucleoli.
We next isolated genomic DNA from the same
samples used above for RNA isolation (20 of the 21
Table 2 Correlations between rRNA species in tumor samples
45S 28S 18S 5.8S
45S — — — —
28S 0.4481 (0.0417) — — —
18S 0.6013 (0.0039) 0.5714 (0.0068) — —
5.8S 0.5844 (0.0054) 0.5597 (0.0083) 0.8584 (o0.0001) —
Shown are the Spearman’s rank correlation coefﬁcients r and
(P-values) for each pair of variables.
HCT116_WT HCT116_KO1
HCT116_KO3b HCT116_DKO
NIM = 0.41 NIM = 0.06
NIM = 0.33 NIM = 0
Figure 3 Methylation status of the rRNA promoter in the
parental colorectal carcinoma cells HCT116 and its derivative
knockout cell lines. The methylation status of each CpG
dinucleotide spanning  158 to þ29bp of human rRNA promoter
in HCT116 colorectal carcinoma cells and derivative lines with
targeted disruption of DNMT1, DNMT3b or both genes. The
rRNA promoter region was ampliﬁed from bisulﬁte-treated
genomic DNA and cloned. The 16–19 randomly selected clones
from each sample were subjected to automated sequencing. Each
row represents the sequence of an individual clone, whereas each
column depicts the position of the CpG. The ﬁlled and open
circles denote methylated and unmethylated CpGs, respectively.
The top row shows a heat map of methylated CpGs representing
the frequency of methylation in each of the individual clones shown
below. The degree of hypermethylation (NIM) at three CpG
islands was assessed using quantitative real-time methylation-
speciﬁc PCR and was normalized to the amount of bisulﬁte-
converted input as described in ‘Materials and methods.’
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Oncogenecases contained enough tissue for DNA isolation).
Figure 5a shows bisulﬁte-sequencing results from these
human prostate cancer specimens as compared with
matched normal specimens. As in the cell lines, all cases
showed two populations of alleles. And, there was no
clear difference in tumor samples compared with normal
samples. A comparison of the methylation pattern of the
20 individual prostates revealed variations among them,
which is likely the result of germ line driven polymorph-
isms in this epigenetic patterning as the differences
between individuals were generally present in both
tumor and normal tissues (Figure 5b). For example,
when comparing tumor with normal samples the
fraction of methylated to total CpGs across the whole
region correlated relatively strongly with each other
(r¼0.7663, P¼0.0001, Pearson’s moment correlation).
It is presently unknown whether this pattern of
individual variation of rDNA promoter methylation
status in humans is also found in other tissues in the
body. When comparing tumor vs normal at individual
CpG sites, there were some relatively subtle differences
uncovered such that there was hypomethylation at  30
and  25 in the core promoter region and hypermethyla-
tion at þ8 in prostate cancer compared with normal
tissues (Figure 5c). Despite these minor changes, it is
clear that demethylation of rDNA promoter regions
does not appear to explain why tumor cell nucleoli are
so enlarged, nor why these cells tend to have increased
numbers of nucleoli.
We next tested whether the overall fraction of
methylated CpGs in the promoter region correlated
with levels of expression of the rRNA species in both
tumor and normal. There was no correlation between
the fraction of CpGs methylated in tumor DNA
(measured across the whole region) with rRNA levels
of any of the rRNA species in the tumor samples
suggesting that in human prostate cancer the levels
of rRNA transcripts do not correlate with the extent of
promoter methylation (not shown). Further, the fraction
of methylated CpGs in the normal tissue did not
correlate with any of the rRNA levels in the normal
tissues, indicating that the polymorphic nature of the
extent of CpG island methylation of the rDNA
promoter does not appear to regulate the levels of
rRNA in human prostate tissues (not shown). Finally,
the fraction of methylated CpGs in tumor or normal
tissues did not correlate with either Gleason score or
pathological stage (not shown). When examining the
fraction of methylated individual CpG sites in tumor or
normal tissue, there were no signiﬁcant correlations
between the extent of methylation at these sites and
rRNA levels (for any species in tumor or normal) when
corrections for multiple testing (Bonferroni) were
performed (not shown).
In a recent study we reported that MYC over-
expression in human and mouse prostate cancer cell
lines was mechanistically related to increased nucleolar
size, number and function (Koh et al., 2010). Further, as
shown in other tissue types, MYC was shown to
positively regulate rRNA levels (Koh et al., 2010).
Therefore, we next performed real time reverse tran-
scriptase PCR of MYC mRNA levels on 19 of the same
samples used for measuring rRNA levels and there was
a signiﬁcant correlation between the levels of MYC and
the 45S (Spearman’s rho¼0.5807, P¼0.0091), the 18S
(Spearman’s rho¼0.5561, P¼0.0134) and the 5.8S
PrEC
VCaP
PC-3
LNCaP
DU145
CWR22
C4-2B
Figure 4 The methylation status of the rRNA promoter in prostate cancer cell lines and normal prostate epithelial cells.
The methylation status for each cytosine within each CpG dinucleotide spanning from  158 to þ29bp of the human rRNA promoter
in prostate cancer cell lines and normal prostate epithelial cells was determined. The rRNA promoter region was ampliﬁed from bisulﬁte-
treated genomic DNA and cloned. The 10–18 randomly selected clones from each sample were subjected to automated sequencing.
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OncogenerRNA species (Spearman’s rho¼0.4895, P¼0.0334),
but not with the 28S species (Spearman’s r¼0.3140,
P¼0.1904).
As rRNA levels were increased in the human prostate
cancer samples, it was of interest to determine whether
these levels related to nucleolar size and number.
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Figure 5 The methylation status of the rRNA promoter in clinical prostate cancer relative to matched normal tissues. (a) The
methylation status of each cytosine within each CpG dinucleotide spanning  158 to þ29bp of the human rRNA promoter in 20
human prostate cancers and matched normal tissues. The rRNA promoter region was ampliﬁed from bisulﬁte-treated genomic DNA
and cloned. The 10–18 randomly selected clones from each sample were subjected to automated sequencing. (b) Quantitative analysis
of methylation density at each CpG and all CpGs with respect to the þ1 site of the rRNA promoter in individual tumors and matched
normal prostate tissues is shown. The percentage of clones methylated and unmethylated at each position among clones is represented
in this bar diagram. T and N denote prostate cancer and normal tissue, whereas Unmet and Met indicate unmethylated and methylated
CpGs, respectively. The average percentage of methylation for all CpG sites at each CpG site, for prostate cancer (N¼20; left-side
bars) and matched normal tissues (N¼20; right-side bars). Data are expressed as *Po0.05; ** Po0.01, measured by w
2-test.
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OncogeneTherefore, we performed immunohistochemical staining
for ﬁbrillarin, a well-known marker of nucleoli, which
we recently reported was directly regulated by MYC and
levels of ﬁbrillarin correlated with MYC protein levels in
clinical samples (Koh et al., 2010). Although levels of
ﬁbrillarin protein did correlate with levels of MYC
mRNA in tumor samples (Spearman’s rho¼0.5702,
P¼0.0108), ﬁbrillarin protein levels in tumor samples
did not correlate with rRNA levels for any of the species
in the tumor samples, albeit levels of ﬁbrillarin in the
non-neoplastic tissues did correlate with levels of the
18S (Spearman’s rho¼0.5421, P¼0.0165) and 5.8S
(Spearman’s rho¼0.4947, P¼0.0313) species in the
non-neoplastic tissues from these same cases.
Discussion
Although it is generally assumed that rRNA levels are
elevated in human cancers, very few clinical samples
have ever been investigated in this regard (Williamson
et al., 2006). In this manuscript we show for the
ﬁrst time that levels of rRNA are elevated in human
prostate cancer clinical specimens as compared with
matched non-neoplastic tissues. What is the mechanism
for such regulation? The current model for transcrip-
tional regulation of ribosomal DNA (rDNA), which is
composed of hundreds of copies of rRNA genes,
proposes two main mechanisms. For short-term regula-
tion, the transcription rate at euchromatic active rDNA
is altered by reversible modiﬁcation of Pol I transcrip-
tion factors that affect the efﬁciency of transcription
initiation and/or the rate of transcription (McStay
and Grummt, 2008; Drygin et al., 2010). Although a
number of pathways that are altered in prostate cancer
could potentially affect nucleolar dynamics (Fischer
et al., 2004), until recently very little was known
regarding which if any of these pathways do affect
prostate cancer nucleoli. Others have previously shown
that MYC can activate rRNA transcription and we
have recently shown that MYC does regulate levels of
45S, 28S, 18S and 5.8S rRNA in human prostate cancer
cells (Koh et al., 2010) (and M Uemura and AM De
Marzo, unpublished observations). In fact, it was shown
that MYC overexpression in both mouse and human
prostate cells results in increased nucleolar size, number,
as well as an increase in a nucleolar program of gene
expression including ﬁbrillarin, nucleolin and UBTF
(Koh et al., 2010). Taken together with previous
studies that have shown that MYC can regulate
nucleolar genes and nucleolar architecture in other cell
types (Schlosser et al., 2003; Grandori et al., 2005;
Grewal et al., 2005), and the present ﬁndings that MYC
mRNA levels correlated with rRNA levels and ﬁbrillarin
protein in the present samples, these results suggest
that MYC overexpression can provide a molecular
mechanism that may explain, at least in part, why
nucleoli are altered in prostatic intraepithelial neoplasia
and prostatic adenocarcinoma. Whether other molecu-
lar alterations that affect the epigenetic state of the
rDNA loci also affect nucleolar dynamics in prostate
cancer, and precisely how MYC can regulate nucleolar
size, number and function awaits additional studies.
Interestingly, recent ﬁndings are beginning to elucidate
how MYC affects rRNA transcription by both induc-
ing gene loop structures in rDNA chromatin that
juxtaposes upstream and downstream rDNA sequences,
as well as, by inducing other changes in chromatin
structure including histone modiﬁcations (Shiue et al.,
2009, 2010).
By contrast to this short-term regulation, in some
cases long-term regulation during development and
differentiation is mediated by epigenetic mechanisms
that consist of recruitment of previously inactive
heterochromatic repeats to become active repeats
(McStay and Grummt, 2008). In the latter case, speciﬁc
chromatin modiﬁcations alter the ratio of active to silent
copies of rRNA genes, thereby adjusting the number of
genes that are involved in transcription (Drygin et al.,
2010). Thus, it is reasonable to hypothesize that the
increased rRNA levels and nucleolar size, number and
function in cancer may relate to recruitment of inactive
repeat units to become active repeats. One previous
study examined this question and reported that in
hepatocellular carcinoma there was an apparent hypo-
methylation of the rDNA promoter region that the
authors indicated could account for increased rRNA
levels (Ghoshal et al., 2004). In the present study in
human prostate cancer, we found that the DNA
methylation status of rDNA promoter region is
essentially unchanged in tumor samples as compared
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Oncogenewith matched normal samples. Thus, such changes
cannot explain differences in rRNA levels or why there
are nucleolar structural abnormalities in prostate cancer.
At present we cannot explain the apparent discrepancy
found in terms of methylation state of the rDNA locus in
prostate cancer as compared with hepatocellular cancer.
Additional studies of the CpG methylation status of these
loci in both of these cancers and other cancers will
be needed to ultimately clarify this issue.
Although all rRNA species were upregulated in
prostate tumors as compared with matched non-
neoplastic tissues, the overexpression reached statistical
signiﬁcance only for the 45S and 5.8S species. At this
time we do not have a molecular explanation for this
apparent discrepancy. In terms of the 45S species, which
is considered to be a sign of new transcription, our
results support the hypothesis that the rate of rRNA
synthesis at this locus is increased in tumor samples.
In terms of the other rRNA species examined, it is well
known that the processing of the 45S transcript into the
mature 28S, 18S and 5.8S species is a multistep process
that is subject to a number of potential modes of
regulation. For example, IGF-1 signaling primarily
effects 18S rRNA processing and thus the function in
the 40S ribosomal subunit, with less effects on the 28S
and 5.8S levels (McMahon et al., 2010). Thus, we expect
that a number of factors regulate steady state levels of
rRNA species in prostate cancer and that the regulation
of each may be somewhat decoupled from each other.
Nevertheless, the levels of all of the different species in a
given patient did correlate fairly strongly with each
other. As a result, it is perhaps more likely that the
reason that not all species reached statistical signiﬁcance
(in terms of overexpression in the cancer tissues) was the
result of the relatively small number of samples that
were assayed in this study.
In summary, we found that rRNA levels are markedly
elevated in human clinical prostate cancer cases, but
there was no evidence, using both prostate cancer cell
lines and a range of clinical specimens, to indicate that
rDNA promoter hypomethylation could be responsible
for either this overexpression or for altered nucleolar
structure and function in prostate cancer.
Materials and methods
Cell culture
LNCaP, PC-3, 22Rv1 and DU 145 cell lines were obtained
from American Type Culture Collection (Rockville, MD,
USA). Prostate epithelial cells were obtained from Lonza
(Basel, Switzerland). C4–2B and VCaP cell lines were
generously provided by Dr John T Isaacs (Johns Hopkins
University, Baltimore, MD, USA). Prostate cell lines were
propagated in RPMI 1640 (Invitrogen, Carlsbad, CA, USA)
containing 10% fetal bovine serum (Hyclone, Waltham, MA,
USA). The HCT116 colorectal carcinoma cell line (HCT116_
WT) and the DNMT1
 /
 (HCT116_KO1), DNMT3b
 /
 
(HCT116_KO3b), and DNMT1
 /
 , DNMT3b
 /
  (HCT116_
DKO) cell lines were generously provided by B Vogelstein and
were grown as previously described (Rhee et al., 2002). All cells
were grown in 5% CO2/95% air at 371C.
Clinical tissue samples
This study was conducted with the approval of the Johns
Hopkins Medical Institutions Institutional Review Board.
Primary prostate cancers were obtained from 21 men under-
going radical prostatectomy at the Johns Hopkins Hospital for
clinically localized prostate cancer (see Table 1). All tissue
samples were obtained by sectioning the prostates immediately
after surgery and identifying regions of cancerous and non-
cancerous tissue that were veriﬁed by frozen section analysis.
All tumor tissues were estimated to be B70–80% tumor cells,
and none of the non-cancerous tissues contained histological
evidence of carcinoma. None of these patients had received
androgen deprivation therapy. These tissues were snap frozen
and stored at  801C. Gleason score, pathological stage and
patient age were collected for each of the subjects at the time of
radical prostatectomy (Table 1).
RNA extraction
RNA was extracted from OCT-embedded frozen tissues using
Trizol (Invitrogen) following the manufacturer’s instructions.
Brieﬂy 5mm frozen tissue sections (n¼50) were treated with
Trizol to obtain a clear lysate solution. After chloroform
extraction, total RNA was recovered from the aqueous phase
by precipitation with isopropyl alcohol. The pellet was washed
by 75% ethanol and dissolved in diethylpyrocarbonate-treated
water. Total RNA was treated with DNAse I (Biolabs, cat#
M0303s) at 371C for 20min to remove trace genomic DNA.
Total RNA was quantiﬁed spectrophotometrically and stored
as aliquots at  801C.
Complementary (c)DNA synthesis
Reverse transcription of RNA was performed using the Bio-
Rad iScript cDNA synthesis kit (Cat. No. 1780–8891) (Bio-
Rad) in a ﬁnal volume of 20ml containing 1  iScript reaction
mix, 1ml RNAse Hþ reverse transcriptase, 200ng total RNA
and nuclease-free water. The samples were incubated at 251C
for 5min and 421C for 30min, and reverse transcriptase was
inactivated by heating at 851C for 5min.
Reverse transcriptase PCR ampliﬁcation
All PCR reactions were performed using Bio-Rad MyiQ single
color Real-Time PCR detection system. For each PCR run
(except for the 45S rRNA precursor), a master mix was
prepared on ice with 1 PCR buffer, 200mm dUTP, 1.5mM
MgCl2, 200nM forward and reverse primer, 0.028 units of
Ampli Taq Gold DNA polymerase (Roche) and 1:100000
SYBR Green (Molecular Probes). A volume of 1mlo f
appropriate diluted cDNA sample was added to 25ml of the
PCR master mix. The thermal cycling conditions comprised an
initial denature step at 951C for 5min, 45 cycles at 951C for
30s, 601C for 30s and 721C for 30s. For the 45S rRNA
precursor we used GreenER qPCR SuperMix (Bio-Rad)
instead of the master mix listed above. Otherwise, the thermal
cycling conditions were the same as above.
Relative copy numbers for each target rDNA gene, MYC
and reference gene (TBP) were determined using the relative
standard curve method (Applied Biosystems User Bulletin #2)
(Applied Biosystems, Foster, CA, USA), with the standard
curve (in triplicate reactions) comprised of serially diluted
cDNA generated after total RNA isolation from PC3 cells.
Each cDNA sample was run in six replicate wells and
appropriate dilute RNAs for each sample were used for
negative controls. rRNA species abundance was normalized to
the abundance of TBP transcripts for each tumor and normal
specimen. All primer sequences are shown in Table 3.
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OncogeneDNA extraction and bisulﬁte treatment
Genomic DNA was extracted from frozen matched pairs of
tumor and normal tissues obtained from the same radical
prostatectomy specimens, as well as from cancer cell lines and
non-neoplastic prostatic prostate epithelial cells using the
DNeasy Kit (QIAGEN, Valencia, CA, USA) and following
the manufacturer’s protocol. In all 500ng of genomic DNA
from cell lines and 10ng of DNA from clinical tissues were
treated with sodium bisulﬁte in order to convert cytosine
residues to uracil using the EZ Methylation Gold-Kit (Zymo
Research, Orange, CA, USA). The converted DNA was eluted
in 40ml of distilled water.
PCR, genotyping and bisulﬁte genomic sequencing
For initial PCR genotyping of the rDNA locus, 1ml
of human male genomic DNA (EMD Chemicals, Gibbstown,
NJ, USA) was ampliﬁed by PCR using platinum Taq DNA
polymerase (Invitrogen). For bisulﬁte DNA sequencing, B1ml
of the post bisulﬁte-treated product was ampliﬁed by PCR
using platinum Taq DNA polymerase (Invitrogen). Each PCR
reaction consisted of a 951C, 4min initial denaturation and
enzyme activation step followed by 35 cycles at 981C for 30s,
501C for 45s (for genotyping PCR, 551C for 45s) and 721C
for 45s, on the i-Cycler IQ (Bio-Rad Laboratories, Hercules,
CA, USA). Bisulﬁte conversion of all the non-methylated
deoxycytosines resulted in the creation of uracil residues that
were later transformed during the PCR ampliﬁcation to
thymine. Because the primers did not contain CpG dinucleo-
tides, methylated and unmethylated sequences ampliﬁed
with equal efﬁciency. The resulting product was excised,
puriﬁed, subcloned and transformed (pCR2.1-TOPO TA
cloning kit, Invitrogen). Plasmid DNA from at least eight
positive clones from the bisulﬁte genomic sequencing product
was sequenced using an ABI 3730 DNA Analyzer (Applied
Biosystems). To ensure that the bisulﬁte conversion was
complete, only clones in which all cytosine residues in non-
CpG dinucleotides had been converted to thymine were
included in the analysis.
Real time methylation-speciﬁc PCR
RT-methylation-speciﬁc PCR was carried out using a pre-
viously described methodology (Yegnasubramanian et al.,
2004). Brieﬂy, sodium bisulﬁte treatment of DNA will result in
conversion of deoxycytidine residues to deoxyuridine unless
the deoxycytidines are methylated at the 50 position. To
ascertain the completeness of the conversion reaction within
the input templates in each sample, bisulﬁte-treated DNA was
ampliﬁed using real-time PCR with oligonucleotide primers
complementary to a region of the MYOD1 promoter that did
not contain any CpG dinucleotides but did contain non-CpG
cytosines. Hypermethylation was then examined by real-time
PCR ampliﬁcation of bisulﬁte-modiﬁed DNA using oligonu-
cleotide primers speciﬁc to a fully methylated bisulﬁte-
converted portion of each CpG island such that only CpG
islands that were methylated at every CpG dinucleotide
interrogated by the primers would be ampliﬁed and generate
a ﬂuorescent signal. All PCR reactions were carried out using
an i-Cycler IQ at 951C for 3min followed by 40 cycles of 951C
for 30s, 541C for 30s and 721C for 45s. The MYOD1
reaction was carried out under the same conditions except
that an annealing temperature of 601C was used. Each PCR
reaction was carried out in a 20ml volume containing 10ml
iQSYBRGreen (Bio-Rad Laboratories), 1mM forward primer,
1mM reverse primer, 1ml of bisulﬁte-modiﬁed DNA. The SssI
methylase is known to methylate deoxycidine residues within
CpG dinucleotides, and this reaction can be driven to
completion. Thus, SssI treatment was used to generate a fully
methylated DNA template in control DNA samples obtained
from donor WBCs as a positive control and was used to
generate a standard curve to quantify the amount of fully
methylated promoter sequences in each reaction. The normal-
ized index of methylation (NIM) was deﬁned as the ratio of the
normalized amount of methylated templates at the promoter
of interest to the normalized amount of converted MYOD1
templates in any given sample. That is,
NIM ¼½ðGENEsampleÞ=ðGENESssIÞ =
½ðMYODIsampleÞ=ðMYODSssIÞ 
where (GENEsample) is the number of fully methylated copies
of the gene of interest in a given sample, (GENESssI) is the
number of fully methylated copies of the gene of interest in the
SssI universally methylated control DNA, (MYOD1sample) is
the number of MYOD1 copies in a given sample, and
(MYOD1SssI) is the number of MYOD1 copies in the SssI
universally methylated DNA. The NIM serves as an index of
Table 3 Primers used in this study
Primer Position Sequence Product Size (bp)
45S rRNA forward 851–868 50-GAACGGTGGTGTGTCGTT-30 130
45S rRNA reverse 961–980 50-GCGTCTCGTCTCGTCTCACT-30
28S rRNA forward 8352–8371 50-AGAGGTAAACGGGTGGGGTC-30 113
28S rRNA reverse 8448–8464 50-GGGGTCGGGAGGAACGG-30
18S rRNA forward 4026–4043 50-GATGGTAGTCGCCGTGCC-30 110
18S rRNA reverse 4119–4135 50-GCCTGCTGCCTTCCTTGG-30
5.8S rRNA forward 6642–6657 50-ACTCGGCTCGTGCGTC-30 136
5.8S rRNA reverse 6762–6777 50-GCGACGCTCAGACAGG-30
TBP forward 50-CACGAACCACGGCACTGATT-30 89
TBP reverse 50-TTTTCTTGCTGCCAGTCTGGAC-30
rDNA genotyping forward 50-GTGTGTCCCGGTCGTAGG-30 420
rDNA genotyping reverse 50-GTCACCGTGAGGCCAGAG-30
rDNA promoter bisulﬁte sequence foward 50-GTTTTTGGGTTGATTAGA-30 229
rDNA promoter bisulﬁte sequence reverse 50-AAAACCCAACCTCTCC-30
rDNA promoter RTMSP forward 50-GGGGTTGATTAGAGGGTTTC-30 189
rDNA promoter RTMSP reverse 50-CAACGTATCAACAATAACCCG A-30
MYOD1 RTMSP forward 50-CCAACTCCAAATCCCCTCTCTAT-30 162
MYOD1 RTMSP reverse 50-TGATTAATTTAGATTGGGTTTAGAGAAGGA-30
mMYC forward 50-CAGATCAGCAACAACCGAAA-30 168
mMYC reverse 50-GGCCTTTTCATTGTTTTCCA-30
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Oncogenethe percentage of bisulﬁte converted input copies of DNA that
are fully methylated at the primer hybridization sites. There-
fore, in diploid samples that are fully methylated at the region
of interest the maximum NIM is 1, and any fraction less than 1
indicates that less than 100% of the templates were methy-
lated. In samples in which the template DNA is completely
unmethylated at the primer sites, the NIM would be 0.
It is important to note that the NIM may be 41 if copies of
MYOD1 are deleted relative to the gene of interest, or copies
of the gene of interest are gained relative to MYOD1 in any
given sample.
Immunohistochemical staining
Immunohistochemical staining and quantitative image analy-
sis of frozen prostate tissue sections from the same specimens
used for RNA isolation and DNA isolation were performed as
described (Koh et al., 2010).
Statistical analyses
All statistical analyses were performed using Stata 8.0 data
analysis and statistical software for Microsoft Windows.
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